Endocrine Abstracts

Introduction: We questioned the justification of general recommendations for assessment of hypopituitarism in patients with traumatic brain injury (TBI), and aimed to describe the prevalence of hypopituitarism in a national TBI population of patients admitted to a Danish hospital in 2008, as compared to healthy controls.Patients and methods: We included 463 patients (18–65 years) hospitalized ≥24 h, with more than subtle TBI as indicated by lo...

Objectives: Hypothyroid patients report a diversity of symptoms at disease presentation. We studied how useful symptoms are to predict hypothyroidism, and if this may vary between subgroups of patients.Methods: Patients newly diagnosed with overt autoimmune hypothyroidism (n=140) were prospectively identified in a population by linkage to diagnostic laboratory databases, and we concomitantly enrolled individually sex and age-region matched contr...

Objective: Our study evaluates the contribution of untreated GHD to the phenotype in controlled CD, by comparing patients with GHD due to CD (n=322) and those with non-functioning pituitary adenoma (NFPA n=748) before and after 3 years of GH treatment.Methods: The patient cohorts were obtained from KIMS (Pfizer International Metabolic Database) and matched for age and gender. Duration between pituitary disease onset and GH start was 9.7 (CD...

Introduction: Autoimmune thyroid disease is associated with other autoimmune diseases. However, most studies are register-based cohort studies or investigate selected patient populations. In a large national cross-sectional population-based study, we investigated positivity of thyroid peroxidase- or thyroglobulin-antibodies (TPOAbs or TgAbs) in association with non-thyroidal autoimmune disease.Methods: As part of The Danish Investigation of Iodine Intake...

Introduction: Prednisolone is standard treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but many patients are reluctant to discontinue prednisolone treatment even after remission of the inflammatory conditions. Prednisolone-induced adrenal insufficiency can give manifest or latent symptoms, causing failure to taper and withdraw prednisolone. We therefore aimed to find the prevalence of adrenal insufficiency in prednisolone-treated patients with PMR/GCA...

This analysis is based on 4457 patients (2365 males, 2092 females; mean age 44 years, range 18-83) with severe GH deficiency (GHD) enrolled in KIMS (pharmaco-epidemiological survey of GH replacement in adult GH-deficient patients, sponsored by Pharmacia Corporation). The mean duration of adult GH replacement was 2.8 years (range 0.1-11.0) giving 10,779 patient years of follow up. The baseline prevalence of diabetes mellitus prior to GH replacement was 3.7 % (compared with popu...

Objective: Hypothalamic obesity results in severe weight-gain and increased risk of cardiovascular and metabolic mortality. We aimed to assess the safety and efficacy of Tesomet (tesofensine plus metoprolol), and ongoing requirements in pituitary hormone replacement adjustments in adults with acquired hypothalamic obesity, a rare disease with no approved therapyResearch design, patients and methodsTwenty-one adults with hypothalami...

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...

Background and aim: The dual-release hydrocortisone Plenadren® has shown promising results of improved cardiovascular and metabolic profiles after treatment of adrenal insufficiency, possibly due to an improved circadian profile of cortisol, but results are ambiguous. Aim: To further investigate the potential effect of dual-release hydrocortisone on the metabolic profile as compared to conventional hydrocortisone in patients with secondary adrenal i...

Background: Pasireotide has proven efficacy in acromegaly and CD, although pasireotide-associated hyperglycaemia occurs in some patients. This Phase IV, randomized, open-label study investigated optimal management of pasireotide-associated hyperglycaemia uncontrolled by metformin/oral antidiabetic therapy (OAD) [NCT02060383].Methods: Adults with acromegaly or CD were enrolled and treated with long-acting pasireotide 40 mg/28 days or subcutaneous pasireot...